Alice Janzen Email & Phone Number

Dallas-Fort Worth Metroplex

2023 and 2024 Axsome Elite Winner. Energy, persistence and passion have helped in my accounts to learn what the customer’s needs are. Offering a solution that best meets the needs of their patients. Consistency in a large geographic territory with excellent follow up.

Dallas, Texas

Promotions of XYWAV, XYREM and SUNOSI for, Narcolepsy, a rare sleep disorder.

Dallas/Ft.Worth, Tx

CEASING PROMOTIONS IN USA IN APRIL.Mulpleta oral for patients with chronic liver disease and thrombocytopenia needing invasive surgery.

Dallas/Fort Worth (Restructuring Of Organization)

Launched Vyvanse® Chewable for ADHD 6+ age group and Mydayis® for ADHD 13+ age groups in Psychiatry and Pediatrics. Vacant territory for 8 months and ranked in the bottom 20%. Collaborated with team, Manager and previous Rep to elevate territory ranking to top 5% in 8 monthso Ranked nationally 6/425 | 117% in Quota Attainment QTD | YTD; 2019o Ranked 6/197 in Pediatric Psychiatry Territories; 2019

Dallas/Fort Worth Area

Introduced Shire to Ophthalmologists and Optometrists in northern Dallas area. Established footprint for Shire’s ophthalmic franchise going forward. Launched Xiidra®, Shire’s first ophthalmic product to physicians. Manage Care and Reimbursement Leado Top Performer for Xiidra® launch; 2016 – 2017o 24% MS in first quarter of launch and increased to 43% by second quartero 1 of 11 representatives nationally to exceed TRx MS Annual Goal of 40% in Q1 of 2017 o Runner Up VP Club - only Rep in top 25 without eye care experience; 2016o Go Big Award - Largest number of prescriptions and writers

Denver, Co

Focused on growing well-established territory in an overall declining market. Utilized excellent product knowledge and physician engagement promoting Lialda® and Pentasa® o Increased Lialda® NRx MS from 30.7% to 41.3% and Lialda® TRx MS 36.4% to 44% in 12 monthso Ranked 9/100 Nationallyo Rep of the Quarter Q2 2014o Ranked 1/7 in region for Highest MS growth and goal attainment Q2; 2014

Dallas/Fort Worth Area

Launched Linzess®, first and only GC-C peptide for Chronic Idiopathic Constipation and Irritable Bowel Syndrome. Launched Viberzi® - first mixed opioid agonist-antagonist for Irritable Bowel Syndrome and Cologuard® Multitarget Stool DNA Testing for Colorectal-Cancer Screening. Focused on growing established territory and rebuilding confidence in newer product. Managed Care Leader for Dallas Team.o Increased Market Share from 32.46 to 42.72% in 15 months; Continually above nation in Quota Attainment; o 101.3% cumulative Quota Attainment

Ft. Worth/Oklahoma/Kansas

Launched Ribasphere Ribapak® for Hepatitis C and Infergen® injectable. Worked closely with specialty pharmacies to pull through.o Increased Market Share NRx from 13.9 -19.45 in first 6 months o Tripled Ribapak sales in first 6 months o Improved ranking from 38 to 8 within 8 months

Mid Cities And N. Dallas

Launched Dexilant®, to Gastroenterology and Primary Care in Dallas-Fort Worth (Mid-Cities). Promoted sales of Amitiza®, Prevacid®, and Lialda®o #1 in Ft. Worth District for Dexilant® launch - Top 20% in nation over 20 weekso Regional Achievement Award - Ranked 4/27 for largest number prescribers for Dexilant launch o Runner-up Cresset Award

Launched Cipro and Cipro IV in the Northwest Houston Area:President's Club Winner | District Trainer | Multiple Rep of the Qtr Top performer for five years. Gained formulary access in 5 hospitals. Worked with physicians and Cipro IV and Tablets were on pre-op and post-of surgery orders.